```html

Wegener’s Nodules (Pulmonary)

Overview

Wegener’s nodules, also known as pulmonary granulomas, are solid lesions that develop in the lungs of people with Granulomatosis with polyangiitis (GPA), formerly called Wegener’s granulomatosis. GPA is a rare, autoimmune vasculitis that primarily attacks small‑ and medium‑sized blood vessels in the respiratory tract and kidneys. When the disease involves the lungs, nodules may form, sometimes cavitating (forming a hollow center) and causing cough, hemoptysis, or chest pain.

Who it affects: GPA can occur at any age but most commonly presents in adults 40‑65 years old. Both sexes are affected, with a slight male predominance (≈55% male). The condition is rare, with an estimated incidence of 3–10 cases per million people per year worldwide [1] NIH, and pulmonary nodules occur in roughly 30‑50% of those patients [2] Mayo Clinic.

Symptoms

Symptoms of pulmonary Wegener’s nodules can be isolated or accompany systemic GPA manifestations. The following list includes the most frequently reported features:

• Persistent cough: dry or productive, often lasting weeks.
• Hemoptysis (coughing up blood): may be mild to massive; more common when nodules cavitate.
• Chest pain: pleuritic (sharp with breathing) or dull, related to inflammation of the pleura.
• Shortness of breath (dyspnea): especially on exertion.
• Fever and chills: low‑grade fevers are common during active disease.
• Weight loss & fatigue: systemic inflammation reduces appetite.
• Ear, nose, and throat (ENT) symptoms: chronic sinusitis, nasal crusting, otitis media—these often precede lung involvement.
• Renal signs: hematuria, proteinuria, or rising creatinine—important to look for because GPA frequently involves the kidneys.
• Skin lesions: palpable purpura or ulcers, signifying systemic vasculitis.
• Joint pain (arthralgia): non‑erosive, migratory.

Causes and Risk Factors

Underlying cause

GPA is an autoimmune disorder. The immune system mistakenly creates antibodies called anti‑neutrophil cytoplasmic antibodies (ANCA), most often directed against proteinase‑3 (PR3‑ANCA). These antibodies activate neutrophils, causing them to adhere to vessel walls, release inflammatory enzymes, and damage the endothelium. The resulting vasculitis leads to necrotizing granulomas—solid nodules—in the lungs.

Risk factors

• Genetics: Certain HLA‑DQ variants increase susceptibility, but a single gene has not been identified.
• Environmental exposures: Silica dust, farming (organic dust), and certain infections (e.g., Staphylococcus aureus colonisation) have been linked to higher GPA risk [3] CDC.
• Smoking: Increases the likelihood of lung involvement and may worsen outcomes.
• Age & sex: Mid‑life adults, slightly more males.
• Previous GPA activity: Patients with prior ENT or renal disease are more likely to develop pulmonary nodules during flares.

Diagnosis

Diagnosing pulmonary Wegener’s nodules requires a combination of clinical, laboratory, imaging, and sometimes histologic information.

Step‑by‑step approach

1. Clinical suspicion: Chronic cough, hemoptysis, or chest pain in a patient with known GPA or ENT/kidney involvement.
2. Laboratory tests:
   • ANCA testing – PR3‑ANCA (c‑ANCA pattern) is positive in 80‑90% of active GPA cases [4] Cleveland Clinic.
   • Complete blood count, ESR/CRP (markers of inflammation), renal function panel, urinalysis.
3. Imaging:
   • Chest X‑ray: May reveal multiple, well‑defined nodules; cavitation in 30‑40% of cases.
   • High‑resolution CT (HRCT): Gold standard for characterising nodules, size, distribution, and cavitation. Typical findings: bilateral, random, ranging from a few millimetres to >5 cm.
4. Bronchoscopy with bronchoalveolar lavage (BAL): Helps exclude infections (TB, fungal) and obtains cytology.
5. Lung biopsy (surgical or VATS): Reserved for atypical cases. Histology shows necrotising granulomatous inflammation with vasculitis.
6. Additional organ assessment: Sinus CT, renal ultrasound, or urine studies to document systemic involvement.

Treatment Options

Treatment aims to control systemic inflammation, shrink nodules, prevent organ damage, and minimise medication toxicity.

Induction therapy (rapid disease control)

• High‑dose glucocorticoids: Oral prednisone 1 mg/kg/day (max 60 mg) or IV methylprednisolone 500–1000 mg daily for 3 days in severe cases.
• Immunosuppressive agents:
  • Rituximab: Anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks (or 1 g on days 0 and 14). Shown non‑inferior to cyclophosphamide for induction [5] NEJM 2020.
  • Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2–3 weeks) for 3–6 months.
  • Methotrexate: For non‑life‑threatening pulmonary disease (≤15 mg/week).

Maintenance therapy (prevent relapse)

• Rituximab (500 mg every 6 months) or azathioprine (2–2.5 mg/kg/day) for 12–24 months, often longer if relapses occur.
• Low‑dose prednisone (≤10 mg/day) tapered gradually.

Adjunctive measures

• Prophylaxis for opportunistic infections: Trimethoprim‑sulfamethoxazole (TMP‑SMX) 1 DS daily reduces Pneumocystis jirovecii pneumonia risk and may lower GPA relapse rates [6] JAMA 2018.
• Bone health: Calcium + vitamin D, bisphosphonates if on long‑term steroids.
• Vaccinations: Influenza, pneumococcal, COVID‑19; avoid live vaccines while immunosuppressed.
• Smoking cessation: Critical to reduce pulmonary complications.

Procedural interventions

• Bronchoscopic laser or electrocautery: For solitary, symptom‑producing nodules causing airway obstruction.
• Surgical resection: Rare, considered only when malignancy cannot be excluded or a nodule causes recurrent massive hemoptysis.

Living with Wegener’s Nodules (Pulmonary)

Living with GPA and lung nodules requires ongoing self‑management and regular follow‑up.

Daily management tips

• Medication adherence: Use a pill organizer, set alarms, and keep a medication list for all providers.
• Monitor symptoms: Record cough, breathlessness, or any blood in sputum. Note new ENT or urinary changes.
• Regular follow‑up: Pulmonology appointment every 3–6 months; labs (CBC, creatinine, ANCA) at each visit.
• Pulmonary rehabilitation: Breathing exercises, aerobic conditioning, and education improve functional capacity.
• Hydration & nutrition: Adequate fluid intake helps thin mucus; a balanced diet supports immune health.
• Stress reduction: Mind‑body techniques (e.g., yoga, meditation) mitigate flare triggers.
• Infection vigilance: Promptly treat upper respiratory infections; seek care if fever or worsening cough occurs.

When to contact your doctor (non‑emergency)

• New or worsening hemoptysis.
• Persistent fever >38 °C for >48 h.
• Significant weight loss (>5 % in 1 month).
• New kidney symptoms (blood in urine, swelling).

Prevention

Because GPA is an autoimmune disease, true primary prevention isn’t possible, but the risk of pulmonary complications can be reduced.

• Stop smoking: Eliminates a key irritant and improves response to therapy.
• Avoid silica and occupational dust: Use protective equipment if exposure unavoidable.
• Maintain up‑to‑date vaccinations: Reduces respiratory infection triggers that can precipitate flares.
• Adhere to prophylactic antibiotics: TMP‑SMX as prescribed lowers infection‑related relapse.
• Early treatment of sinus disease: Aggressive management of ENT infection lowers systemic immune activation.

Complications

If pulmonary Wegener’s nodules are untreated or inadequately controlled, several serious complications can arise:

• Massive hemoptysis: Cavitated nodules can erode vessels, leading to life‑threatening bleeding.
• Progressive pulmonary fibrosis: Chronic inflammation may scar lung tissue, causing irreversible loss of function.
• Respiratory failure: Diffuse disease can impair gas exchange, especially when combined with renal insufficiency.
• Secondary infections: Immunosuppression augments risk of bacterial, fungal, or viral pneumonia.
• Renal failure: Systemic vasculitis often involves glomeruli; uncontrolled disease leads to end‑stage renal disease.
• Malignancy: Long‑term cyclophosphamide exposure is associated with bladder cancer; regular screening is advised.
• Medication‑related toxicity: Steroid‑induced diabetes, osteoporosis, and avascular necrosis.

When to Seek Emergency Care

References

1. National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Granulomatosis with polyangiitis (Wegener’s).” NIH, 2023.
2. Mayo Clinic. “Granulomatosis with polyangiitis (Wegener’s).” Updated 2024.
3. Centers for Disease Control and Prevention. “Silica and other occupational exposures linked to autoimmune disease.” 2022.
4. Cleveland Clinic. “ANCA‑Associated Vasculitis: Diagnosis & Treatment.” 2023.
5. Smith RJ et al. “Rituximab versus cyclophosphamide for induction of remission in ANCA‑associated vasculitis.” New England Journal of Medicine. 2020;382:1303‑1315.
6. Walsh M et al. “Trimethoprim‑sulfamethoxazole reduces relapse in GPA.” JAMA. 2018;319(23):2415‑2424.

```